Effect of SEN virus coinfection on outcome of lamivudine therapy in patients with hepatitis B.
OBJECTIVE
Interactions between hepatitis B virus (HBV) and other viral hepatitis infections are well known, whether the newly discovered SEN virus (SENV) has any effect on lamivudine antiHBV activity is unclear. Our aim was to clarify the effect on treatment outcome of coinfection with SEN virus in patients with hepatitis B during lamivudine therapy.


METHODS
Nested polymerase chain reaction (PCR) amplification was used to detect SENV-D and SENV-H strains in serum from 45 patients with chronic hepatitis B treated with lamivudine 100 mg daily for 12 mo. HBV DNA load was detected with fluorescence quantitative PCR (FQ-PCR) and YMDD (tyrosine, methionine, aspartate, aspartate) motif mutation of HBV DNA was investigated with cDNA microarray.


RESULTS
SENV DNA was detected in 5 of 45(11.1%) cases after 12 mo they received lamivudine treatment. SENV-D and SENV-H were 4.4% and 6.7% respectively. HBV DNA failed to respond to lamivudine therapy in 4 of 5 SENV coinfected patients while only 10 of 40 patients became SENV positive and the difference was statistically significant. Response of ALT and HBeAg to lamivudine had no significant difference between coinfection patients and single HBV infection ones.


CONCLUSIONS
Coinfection with SEN virus in chronic hepatitis B patients may adversely affect the outcome of lamivudine treatment.
Xu
Dong
D
Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Street 1095, Wuhan 430030, Hubei Province, China. xudongtj@tom.com
Tian
De-Ying
DY
Zhang
Zhen-Gang
ZG
Chen
Hong-Yun
HY
Song
Pei-Hui
PH
D000328:Adult; D004266:DNA Virus Infections / Q000150:complications*; D006509:Hepatitis B / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine